59,58 €
Deine Einschätzung
Corcept Therapeutics Inc. Aktie
Was spricht für und gegen Corcept Therapeutics Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Corcept Therapeutics Inc. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Inc. | 0,41 % | 14,80 % | 49,29 % | -11,84 % | -12,87 % | 165,98 % | 234,72 % |
| Rockwell Medical Inc. | 0,00 % | -2,99 % | -14,47 % | -20,54 % | -3,92 % | -70,11 % | -91,59 % |
| Pacira Pharmaceuticals | 1,00 % | 1,51 % | -5,61 % | -9,82 % | -6,48 % | -43,89 % | -58,78 % |
| Twist Bioscience Corp | 1,25 % | 9,85 % | 18,02 % | 128,82 % | 105,82 % | 326,81 % | -34,88 % |
Kommentare
News
Why Corcept Therapeutics Zoomed Nearly 9% Higher This Week
One of the top-performing healthcare stocks mid-week was Corcept Therapeutics (NASDAQ: CORT), and it was little wonder -- the company was granted U.S. Food and Drug Administration (FDA) approval for
Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday
Corcept Therapeutics (NASDAQ: CORT) took its investors for quite a ride on Hump Day. The commercial-stage biotech earned its latest nod from a regulator that afternoon and, not surprisingly, its
Corcept Insider Transaction Explained After Shares Tumble 50% in One Day
On Tuesday, William Guyer, the chief development officer of Corcept Therapeutics (NASDAQ:CORT), exercised and immediately sold 20,000 shares through open-market transactions totaling approximately




